Case report:

Primary Non-Hodgkin's Orbital lymphoma of diffuse large B-cell type: a rare presentation

Parikshit M¹, Ayan B², Yogiraj R³, Mehebubar R⁴, Prosad GR⁵

Abstract:

Primary Non-Hodgkin's lymphoma of the orbit is a rare presentation and the diffuse large B-cell lymphoma (DLCL) type of histology is much less commoner than the mucosa associated lymphoid tissue (MALT) and follicular lymphoma. A 70 years female patient presented with palpable mass arising from right orbit and proptosis of the right eye. CT scan suggested homogenous enhancing soft tissue mass affecting right lacrimal region without any bony destruction. Biopsy confirmed it to be a case of Primary non-Hodgkin's lymphoma of diffuse large B-cell type with strongly positive CD 20. She was given 6 cycles of chemotherapy with R-CHOP after surgery. The patient is now asymptomatic one year after the last cycle of the chemotherapy.

Key-words:

Non-Hodgkin's lymphoma (NHL); diffuse large B-cell lymphomas (DLCL); orbit; chemotherapy

Key Messages:

Primary Non-Hodgkin's lymphoma of the orbit is rare and DLCL type of histology is much rarer. It can occur in orbit without any systemic features. It must be diagnosed early and can be treated successfully by surgery and R CHOP chemotherapy

Bangladesh Journal of Medical Science Vol. 15 No. 04 October'16

Introduction:

Lymphomas are malignant neoplasm lymphoreticular system and mainly involve lymph nodes, spleen and other non-haemopoietic tissues. Eighty percent of lymphomas are B-cell type, while 14% are T-cell type, with natural killer type (NK) forms only six percent 1. Primary orbital Non-Hodgkin's Lymphoma is a rare presentation of extranodal non-Hodgkin's lymphoma accounting for less than one percent of NHL ². It affects primarily the lacrimal glands, conjunctiva, eyelids and orbits 3. Diffuse large B-cell lymphoma (DLCL) type of histology is much less commoner types of primary orbital NHL.

Case History

A seventy years old female patient presented with a gradually increasing painless mass over the right eyelid for last five months before admission. She was unable to open her right eye, decreased vision and proptosis of the right eye. There was no history of fever, night sweats, significant weight loss, weakness, anorexia, past history of tuberculosis or contact and neither she was immunocompromised nor on any immunosuppressive drugs. Prior history of exposure to radiation was absent. On general examination, she had mild pallor. The swelling was 5.0 x 3.0 cm, oval, involving mainly the upper and outer aspect of the right eye, and extended to involve the major part of the eyelid (Figure 1).

- 1. Mullick Parikshit, Post Graduate Trainee
- 2. Basu Ayan, RMO cum Clinical Tutor
- 3. Roy Yogiraj, Assistant Professor
- 4. Rahman Mehebubar, Associate Professor
- Goswami Rama Prosad, Professor
 Department of Tropical Medicine, School of Tropical Medicine, Kolkata

<u>Corresponds to:</u> Dr Ayan Basu, 46/27A, Becharam Chatterjee Road, Behala, Kolkata-700034, WestBengal, E-mail – ayanbasustm@gmail.com



Fig 1- Patient before treatment

It was firm in consistency, non-tender, attached to superficial skin and underlying structures without any discharging sinus or overlying ulcer. Superficial temperature was not raised, no thrill or pulsation was noted and no bruit was found. On systemic examination, there was no organomegaly without any lymphadenopathy, neither mediastinal dullness nor any features of superior vena caval obstruction. There was no cranial nerve involvement. Peripheral blood smear showed no abnormal cells. Haemoglobin was 9.8 g/dl, serum LDH was 677 U/l. Other routine laboratory tests like blood glucose, urea, creatinine, liver function test, uric acid, calcium, chest X-ray, echocardiography, and upper gastrointestinal endoscopy were normal. HIV serology was nonreactive. She was further investigated by Contrast enhanced CT Scan of Orbit along with the Paranasal Sinuses which revealed an extraconal lobulated homogenously enhancing soft tissue mass in the right orbit in lacrimal region. The lesion appeared to be exophytic, protruding to superolateral aspect of the right orbit, medially extending along the superior aspect of the right orbit investing the anterior wall of right globe involving superior oblique muscle and superior rectus – levator palpebrae muscle complex without significant mass effect over right globe (Figure 2, 3, 4).



Fig 2- CECT orbit Axial view



Fig 3- CECT orbit Oblique view



Fig 4- CECT orbit Coronal view

She was provisionally diagnosed as a case of Primary Orbital lymphoma and underwent for debulking surgery for removal of the mass. The tissue sample was sent for histopathological examination, which revealed Non-Hodgkin's lymphoma of diffuse large B cell type and immuno-histochemistry confirmed the diagnosis with CD 20 strongly positive; CD 23, CD 3 & CD 5 negative. She was prescribed with 6 cycles of chemotherapy with R-CHOP (considering her height 4' 11", body weight 50kgs, body surface area 1.44m2); Inj. Rituximab (375 mg/m2 = 540 mg), Inj. Cyclophosphamide (750mg/m2 = 1080mg), Inj Doxorubicin (40 mg/m2 = 60 mg), Inj. Vincristine (1.4 mg/m2 = 2 mg) and Tablet Prednisolone (100 mg). She had been asymptomatic thereafter and no further recurrence noted on one year follow-up (Figure 5)



Fig 5- Patient after treatment

Discussion:

Orbital lymphoma is a lymphoma occurring in the conjunctiva, lacrimal gland, eyelid and ocular musculature. Primary non-Hodgkin's lymphoma (NHL) of the orbit is a rare presentation, representing 8-10% of extranodal NHL 3 and only 1% of all NHL 2. Generally, it has an indolent course. Orbital and adnexal lymphoma is associated with systemic lymphoma in 30-35% of cases. Hence, all patients with ocular lymphoma should have a complete workup to rule out systemic lymphoma. The usual presentation of intraocular lymphoma is decreased vision with nonresolving uveitis, along with proptosis and visible conjunctival mass. It may be of following histology: mucosa associated lymphoid tissue (MALT)

histology (57%), follicular lymphomas (19%), diffuse large B-cell lymphomas (DLCL), mantle cell lymphomas, B-cell chronic lymphocytic leukemia, peripheral T-cell lymphoma, and natural killer cell lymphoma. Out of which occular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma (57%) is the commonest one, and it's usually associated with Chlamydia psittaci 2, 4, 6. Majority of the orbital lymphomas are of lowgrade variety (84%) and only 16% are of high-grade histology 5. Orbital lymphoma may be unilateral or bilateral and up to 20% bilateral presentation is noted. Although intraorbital lymphoma is rare, the number of cases per year is rising, affecting mainly people in their seventies 7, 8 and immunocompromised patients 9, 10. A recent study has shown that ocular lymphoma is more prevalent in women than men11. The survival rate is approximately 60% after 5 years. Total or subtotal excision of the mass followed by radiotherapy and/ or chemotherapy has a better outcome in these patients. However, radiation exposure predisposes to the development of cataracts after 3 – 8 years. As MALT lymphoma has the best prognosis, DLCL prognosis can be improved by early prompt diagnosis and combination chemotherapy. The role of radiotherapy in DLCL is unclear. Combination chemotherapy with CHOP is quite efficacious, while addition of intravenous rituximab (anti CD 20 monoclonal antibody) in the regimen helps in rapid remission with good results 12, 13. As the patient is CD 20 strongly positive, we had chosen rituximab as the chemotherapeutic agent along with other chemotherapeutic agents. The patient is asymptomatic even after one year of last dose of chemotherapy.

Conclusion:

Lymphoma can occur in the orbit without any systemic manifestations. A palpable painless mass of an eye particularly in elderly female must be diagnosed early in case of an orbital lymphoma before any bony destruction starts and that will improve the prognosis of the patient. In case of DLCL though a rare form, can be treated with the surgical debulking followed by combination chemotherapy. R-CHOP chemotherapy regimen is quite efficacious in treating the case, without any recurrence at 1 year follow-up.

Conflict of interest : None

Acknowledgement:

Department of Tropical Medicine, School of Tropical Medicine

Ethical approval:

This case report was published with prior ethical approval from the authority of School of Tropical Medicine

References:

- Fitzpatrick PJ, Macko S. Lymphoreticular tumors of the orbit. Int J Radiat Oncol Biol *Physics*. 1984; 10: 333–40.
- Coupland SE, Hummel M, Stien H. Ocular adnexal lymphomas: Five case presentation and a review of literature. Surv Ophthalmol. 2002; 47: 470–90
- 3. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. *Cancer*. 1972; **29**: 252–60
- Fung CY, Tarbell NJ, Lucarelli MJ, Goldberg SI, Linggood RM, Harris NL, et al. Ocular adnexal Lymphoma: Clinical behaviour of distinct world health organization classification of subtypes. *Int J Rad Oncol Biol Phys*. 2003; 57: 1382–91.
- 5. Bessel EM, Henk JM, Wright JE, Whitelocke RA. Orbital and conjunctival lymphoma: Treatment and prognosis. *Radither Oncol.* 1988; **13**: 237–44.
- Ferreri AJ, Guidoboni M, Ponzoni M et-al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J. Natl. Cancer Inst. 2004; 96 (8): 586-94
- Moslehi, R.; Devesa, S. S.; Schairer, C.; Fraumeni, J. F. (July 2006). "Rapidly Increasing Incidence of Ocular Non-Hodgkin Lymphoma". JNCI Journal of the National

Cancer Institute. 98 (13): 936-939

- Demirci, H; Shields, CL; Shields, JA; Honavar, SG; Mercado, GJ; Tovilla, JC (February 2002). "Orbital tumors in the older adult population". Ophthalmology 109 (2): 243–8
- Burnier MN Jr, Stockl FA, Dolmetsch AM. Large B-cell lymphoma of the retina and CNS. Presented at the 1994 Annual Meeting of the Eastern Ophthalmic Pathology Society, Boston, Mass. October 1994.
- 10. Schabet, M (July 1999). "Epidemiology of primary CNS lymphoma". *Journal of neuro-oncology* **43** (3): 199–201
- 11. Ahmed, S; Shahid, RK; Sison, CP; Fuchs, A; Mehrotra, B (February 2006). "Orbital lymphomas: a clinicopathologic study of a rare disease". The American journal of the medical sciences **331** (2): 79–83
- Benabid L, Desablens B, Defossez T, Malthieu D, Milazzo S, Turut P. [New treatment for orbital non-Hodgkin's lymphoma: 2 cases treated with rituximab]. J Fr Ophtalmol. Sep 2005; 28 (7): 769-71.
- 13. Savino G, Battendieri R, Gari M, Caputo CG, Laurenti L, Blasi MA. Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections. *J Cancer Res Clin Oncol*. Apr 27 2013.